Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil (OmitMMF)
IIT2021-11-PAQUETTE-OmitMMF: Fludarabine and Total Body Irradiation 800 cGy or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
This is a pilot study to evaluate the feasibility, safety and potential benefits of removing one immune suppressive drug called mycophenolate mofetil (MMF) from the standard allogenic stem cell transplant treatment protocol.
MMF will be omitted from the transplant regimen in 60 eligible patients with hematologic malignancies. Participants will be followed for up to 2 years post standard of care transplant at Cedars-Sinai.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Amy Oppenheim
- Phone Number: 310-423-3713
- Email: Amy.Oppenheim@cshs.org
Study Contact Backup
- Name: Ronald Paquette, MD
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient age 18-75 years
- Patient has a related donor who is at least Human Leukocyte Antigen (HLA) haploidentical, or an unrelated donor who is a most a single HLA antigen mismatch.
- Patient signs the Informed Consent Form for the study
- Patient has a hematologic malignancy other than myelofibrosis and meets standard criteria for allogeneic stem cell transplant.
- Patient is deemed suitable to receive Fludarabine and Total Body Irradiation (Flu/TBI) 1125 or Flu/TBI 800 conditioning regimen as standard of care transplant
- Donor is willing to donate peripheral blood stem cells
Exclusion Criteria:
- Patient has a diagnosis of myelofibrosis
- Patient has high titer antibodies against one or more donor HLA antigens
- Patient has undergone prior autologous or allogeneic stem cell transplant.
- Inability to collect sufficient peripheral blood stem cells from the donor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Open Arm
Omission of the drug mycophenolate mofetil
|
Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Engraftment failure
Time Frame: 60 days post-transplant
|
Evaluate the feasibility of eliminating the drug Mycophenolate Mofetil (MMF) from the transplant regimens as determined by an acceptable rate of engraftment failure (<10%).
Engraftment failure is when the blood-forming cells received on transplant day do not start to grow and make healthy blood cells.
|
60 days post-transplant
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to neutrophil and platelet engraftment
Time Frame: 60 days post-transplant
|
Days to neutrophil and platelet engraftment since transplant.
|
60 days post-transplant
|
|
Rate of severe acute GVHD by day +100.
Time Frame: 100 days post-transplant
|
Proportion of patients with severe acute GVHD at day 100 post-transplantation.
|
100 days post-transplant
|
|
Treatment-related mortality
Time Frame: 5 days post- transplant to 2-years
|
Rate of treatment-related mortality
|
5 days post- transplant to 2-years
|
|
Rate of severe chronic GVHD at 1 year
Time Frame: 1-year post-transplant
|
Proportion of patients with severe chronic GVHD at day 365 post-transplantation. -Chronic GVHD is when the donated stem cells attack the body after 100 days post-transplant. Chronic GVHD is defined by NIH Consensus Criteria for chronic GVHD. |
1-year post-transplant
|
|
Relapse
Time Frame: 1 year post-transplant and 2 years post-transplant
|
Relapse rate at 1 and 2 years
|
1 year post-transplant and 2 years post-transplant
|
|
Overall Survival (OS)
Time Frame: 1-year post-transplant and 2-years post-transplant
|
Overall survival at 1 and 2 years
|
1-year post-transplant and 2-years post-transplant
|
|
Graft Versus Host Disease (GVHD)-free, Relapse Free Survival
Time Frame: 1-year post- transplant and 2-years post-transplant
|
Rate of GVHD-free, Relapse Free Survival
|
1-year post- transplant and 2-years post-transplant
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ronald Paquette, MD, Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Hematologic Diseases
- Hemic and Lymphatic Diseases
- Hematologic Neoplasms
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibiotics, Antineoplastic
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antibiotics, Antitubercular
- Antitubercular Agents
- Mycophenolic Acid
Other Study ID Numbers
Other Study ID Numbers
- IIT2021-11-PAQUETTE-OmitMMF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.